Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 207

1.

Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice.

Mayer LD, Harasym TO, Tardi PG, Harasym NL, Shew CR, Johnstone SA, Ramsay EC, Bally MB, Janoff AS.

Mol Cancer Ther. 2006 Jul;5(7):1854-63.

PMID:
16891472
[PubMed - indexed for MEDLINE]
Free Article
2.

Increased preclinical efficacy of irinotecan and floxuridine coencapsulated inside liposomes is associated with tumor delivery of synergistic drug ratios.

Harasym TO, Tardi PG, Harasym NL, Harvie P, Johnstone SA, Mayer LD.

Oncol Res. 2007;16(8):361-74.

PMID:
17913044
[PubMed - indexed for MEDLINE]
3.

Drug ratio-dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivo.

Tardi PG, Dos Santos N, Harasym TO, Johnstone SA, Zisman N, Tsang AW, Bermudes DG, Mayer LD.

Mol Cancer Ther. 2009 Aug;8(8):2266-75. doi: 10.1158/1535-7163.MCT-09-0243. Epub 2009 Aug 11.

PMID:
19671743
[PubMed - indexed for MEDLINE]
Free Article
4.

In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy.

Tardi P, Johnstone S, Harasym N, Xie S, Harasym T, Zisman N, Harvie P, Bermudes D, Mayer L.

Leuk Res. 2009 Jan;33(1):129-39. doi: 10.1016/j.leukres.2008.06.028. Epub 2008 Aug 3.

PMID:
18676016
[PubMed - indexed for MEDLINE]
5.

Schedule- and dose-dependency of CPX-351, a synergistic fixed ratio cytarabine:daunorubicin formulation, in consolidation treatment against human leukemia xenografts.

Lim WS, Tardi PG, Xie X, Fan M, Huang R, Ciofani T, Harasym TO, Mayer LD.

Leuk Lymphoma. 2010 Aug;51(8):1536-42. doi: 10.3109/10428194.2010.490312.

PMID:
20528246
[PubMed - indexed for MEDLINE]
6.

Drug ratio-dependent antagonism: a new category of multidrug resistance and strategies for its circumvention.

Harasym TO, Liboiron BD, Mayer LD.

Methods Mol Biol. 2010;596:291-323. doi: 10.1007/978-1-60761-416-6_13. Review.

PMID:
19949929
[PubMed - indexed for MEDLINE]
7.

Optimizing combination chemotherapy by controlling drug ratios.

Mayer LD, Janoff AS.

Mol Interv. 2007 Aug;7(4):216-23. Review.

PMID:
17827442
[PubMed - indexed for MEDLINE]
8.

In vitro and in vivo characterization of a combination chemotherapy formulation consisting of vinorelbine and phosphatidylserine.

Webb MS, Johnstone S, Morris TJ, Kennedy A, Gallagher R, Harasym N, Harasym T, Shew CR, Tardi P, Dragowska WH, Mayer LD, Bally MB.

Eur J Pharm Biopharm. 2007 Mar;65(3):289-99. Epub 2006 Oct 17.

PMID:
17123800
[PubMed - indexed for MEDLINE]
9.

Liposomal irinotecan: formulation development and therapeutic assessment in murine xenograft models of colorectal cancer.

Messerer CL, Ramsay EC, Waterhouse D, Ng R, Simms EM, Harasym N, Tardi P, Mayer LD, Bally MB.

Clin Cancer Res. 2004 Oct 1;10(19):6638-49.

PMID:
15475454
[PubMed - indexed for MEDLINE]
Free Article
10.

Antitumour effect of combination treatment with Sabarubicin (MEN 10755) and cis-platin (DDP) in human lung tumour xenograft.

Bigioni M, Benzo A, Irrissuto C, Lopez G, Curatella B, Maggi CA, Manzini S, Crea A, Caroli S, Cubadda F, Binaschi M.

Cancer Chemother Pharmacol. 2008 Sep;62(4):621-9. Epub 2007 Nov 24.

PMID:
18038274
[PubMed - indexed for MEDLINE]
11.

Optimization of vincristine-topotecan combination--paving the way for improved chemotherapy regimens by nanoliposomes.

Zucker D, Barenholz Y.

J Control Release. 2010 Sep 15;146(3):326-33. doi: 10.1016/j.jconrel.2010.05.024. Epub 2010 May 25.

PMID:
20685223
[PubMed - indexed for MEDLINE]
12.

Enhancement of in vivo antitumor activity of classical anticancer agents by combination with the new, glutathione-interacting DNA minor groove-binder, brostallicin.

Sabatino MA, Colombo T, Geroni C, Marchini S, Broggini M.

Clin Cancer Res. 2003 Nov 1;9(14):5402-8.

PMID:
14614026
[PubMed - indexed for MEDLINE]
Free Article
13.

Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo.

Tardi PG, Gallagher RC, Johnstone S, Harasym N, Webb M, Bally MB, Mayer LD.

Biochim Biophys Acta. 2007 Mar;1768(3):678-87. Epub 2006 Dec 6.

PMID:
17208196
[PubMed - indexed for MEDLINE]
Free Article
14.

Use of nanoscale delivery systems to maintain synergistic drug ratios in vivo.

Dicko A, Mayer LD, Tardi PG.

Expert Opin Drug Deliv. 2010 Dec;7(12):1329-41. doi: 10.1517/17425247.2010.538678. Review.

PMID:
21118030
[PubMed - indexed for MEDLINE]
15.

Safety, pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumors.

Batist G, Gelmon KA, Chi KN, Miller WH Jr, Chia SK, Mayer LD, Swenson CE, Janoff AS, Louie AC.

Clin Cancer Res. 2009 Jan 15;15(2):692-700. doi: 10.1158/1078-0432.CCR-08-0515.

PMID:
19147776
[PubMed - indexed for MEDLINE]
Free Article
16.

Selective modulation of the therapeutic efficacy of anticancer drugs by selenium containing compounds against human tumor xenografts.

Cao S, Durrani FA, Rustum YM.

Clin Cancer Res. 2004 Apr 1;10(7):2561-9.

PMID:
15073137
[PubMed - indexed for MEDLINE]
Free Article
17.

Pharmacokinetics of CPX-351 (cytarabine/daunorubicin HCl) liposome injection in the mouse.

Bayne WF, Mayer LD, Swenson CE.

J Pharm Sci. 2009 Jul;98(7):2540-8. doi: 10.1002/jps.21620.

PMID:
19009594
[PubMed - indexed for MEDLINE]
18.

Preclinical pharmacokinetic/pharmacodynamic models to predict synergistic effects of co-administered anti-cancer agents.

Goteti K, Garner CE, Utley L, Dai J, Ashwell S, Moustakas DT, Gönen M, Schwartz GK, Kern SE, Zabludoff S, Brassil PJ.

Cancer Chemother Pharmacol. 2010 Jul;66(2):245-54. doi: 10.1007/s00280-009-1153-z. Epub 2009 Oct 16.

PMID:
19841922
[PubMed - indexed for MEDLINE]
19.

Chemosensitization and radiosensitization of human lung and colon cancers by antimitotic agent, ABT-751, in athymic murine xenograft models of subcutaneous tumor growth.

Jorgensen TJ, Tian H, Joseph IB, Menon K, Frost D.

Cancer Chemother Pharmacol. 2007 May;59(6):725-32. Epub 2006 Sep 12.

PMID:
16967299
[PubMed - indexed for MEDLINE]
20.

The formulation of lipid-based nanotechnologies for the delivery of fixed dose anticancer drug combinations.

Ramsay EC, Dos Santos N, Dragowska WH, Laskin JJ, Bally MB.

Curr Drug Deliv. 2005 Oct;2(4):341-51. Review.

PMID:
16305437
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk